| Biotech Due Diligence |
|
|
Courtesy of @zDonShimoda, this post features PI3K inhibitor presentations upcoming at the International Conference on Malignant Lymphoma to be held June 19-22, 2013 in Lugano, Switzerland. Featured companies include Infinity Pharma INFI, Gilead GILD, and Pharmacyclics PCYC (partnered with Johnson & Johnson JNJ).
You can also find #ASCO13 PI3K abstracts here.
0 Comments
Astex Pharma ASTX derives all of its royalty revenue from sales of DACOGEN (decitabine) by partners Janssen (JNJ) and Eisai. The key competitor in the ypomethylator space is VIDAZA (azacytidine) from Celgene CELG. The latest updates on the market can be found below.
Also note that JNJ, as usual, did not mention DACOGEN on their earnings call, nor did they break out sales in their earnings release. Continue reading below for a variety of comments from competitors and collaborators of Astex Pharma ASTX from 3q-2012 earnings conference calls
Merck today announced details [link] about the new phase 2/3 (200 then 1700 patients) clinical trial in mild-to-moderate Alzheimer’s Disease testing the BACE inhibitor MK-8931. This trial will be yet another test of the “amyloid hypothesis” for AD – investors, patients, and researchers will be hoping it goes better than recent trials from Eli Lilly's $LLY solanezumab, and bapineuzumab from Pfizer $PFE – Johnson & Johnson $JNJ – Elan $ELN.
You can find more details on the program in my highlights from a recent Merck R&D day event [link]. Recall that this program is licensed from Ligand Pharma $LGND (well, it arose two mergers ago in a drug discovery deal between Schering Plough $SGP and Pharmacopeia $PCOP). Check the archive of LGND-related posts to see what MRK has said about the program at other events and webcasts. Continue reading for the complete info and data from four abstracts about the drug presented at the AAIC meeting earlier in 2012. See comments below from Celgene $CELG 2q-2012 conference call (transcript via SeekingAlpha) related to VIDAZA, the key competitor to DACOGEN, Astex Pharma's myelodysplastic syndome (MDS) drug licensed to Eisai and Johnson & Johnson $JNJ. Note that both ASTX and Celgene are also developing "next-generation" verisions of their drug. See more about SGI-110 here.
"Compared to the second quarter of 2011, the significant increase in gross margin is partly due to a decrease in VIDAZA royalties after the product's loss of exclusivity in the U.S. in May of 2011." "Second quarter VIDAZA sales were a record $201 million. Sequential quarterly sales grew 8% with strong year-on-year growth of 24%. In the U.S., sequential quarterly sales increased by 12% to $82 million and 12% year-on-year. Second quarter international VIDAZA sales grew to $119 million, up 6% quarter-on-quarter and 25% year-on-year. We expect new markets and increasing market share, plus duration of treatment in those existing markets, to drive improved international VIDAZA sales." "We continually work to optimize and leverage our global MDS franchise. Our Phase III registration study for VIDAZA in acute myeloid leukemia is advancing and should serve to expand its approved indication to include all categories of patients with AML. Investigator interest to conduct research with CC-486, or oral azacitidine, is very high with 2 specific strategies under active consideration. The first seeks to develop CC-486 for a subset of low-risk MDS, and the other will test CC-486 as maintenance therapy following transplantation or other induction therapy for AML." |
Categories
All
Archives
January 2020
|
RSS Feed
